Edition:
United States

Diplomat Pharmacy Inc (DPLO.N)

DPLO.N on New York Stock Exchange

24.15USD
24 May 2018
Change (% chg)

$-0.10 (-0.41%)
Prev Close
$24.25
Open
$24.17
Day's High
$24.43
Day's Low
$23.80
Volume
95,106
Avg. Vol
194,433
52-wk High
$27.73
52-wk Low
$14.24

Chart for

About

Diplomat Pharmacy, Inc. (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company's primary focus is on medication management programs... (more)

Overall

Beta: 1.36
Market Cap(Mil.): $1,789.10
Shares Outstanding(Mil.): 74.08
Dividend: --
Yield (%): --

Financials

  DPLO.N Industry Sector
P/E (TTM): 562.15 29.96 32.60
EPS (TTM): 0.04 -- --
ROI: 0.27 7.64 12.74
ROE: 0.42 10.96 14.66

BRIEF-Diplomat Pharmacy Posts Q4 Adj. Earnings Per Share $0.18

* DIPLOMAT ANNOUNCES 4TH QUARTER AND 2017 YEAR END FINANCIAL RESULTS; PROVIDES 2018 GUIDANCE

Feb 26 2018

BRIEF-Diplomat Pharmacy Says Dispensing Advanced Kidney Treatment, CABOMETYX

* DIPLOMAT PHARMACY INC - ‍IS DISPENSING EXELIXIS' LIMITED-DISTRIBUTION TREATMENT CABOMETYX NOW WITH AN EXPANDED INDICATION​ Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

Jan 15 2018

BRIEF-Diplomat Reaffirms 2017 Guidance And Provides Preliminary 2018 Outlook

* DIPLOMAT PHARMACY INC - ‍JEFF PARK, HAS BEEN APPOINTED INTERIM CHIEF EXECUTIVE OFFICER, EFFECTIVE IMMEDIATELY​

Jan 05 2018

BRIEF-Diplomat Reaffirms 2017 Guidance, Provides Preliminary 2018 Outlook

* - EXPECTS 2017 REVENUE TO BE NEAR MIDDLE OF PREVIOUSLY PROVIDED RANGE

Jan 05 2018

BRIEF-Diplomat Completes Acquisition Of LDI Integrated Pharmacy Services

* DIPLOMAT COMPLETES ACQUISITION OF LDI INTEGRATED PHARMACY SERVICES, SECURES NEW CREDIT FACILITIES

Dec 20 2017

BRIEF-Diplomat Adds Chris Luthin As Executive Vice President

* DIPLOMAT ADDS CHRIS LUTHIN AS EXECUTIVE VICE PRESIDENT Source text for Eikon: Further company coverage:

Dec 11 2017

Earnings vs. Estimates